Related Experiment Videos
Immunosuppressive effects of statins
1Medicine Department, Cardiology Division, Foundation for Medical Research, Geneva Medical School, University Hospital, 64 Avenue Roseraie, 1211 Geneva, Switzerland.
Insights
Statins, commonly used for lowering lipids, surprisingly inhibit the induction of Major Histocompatibility Complex class II (MHC class II) molecules. This action positions statins as novel immunomodulators with potential immunosuppressive applications.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Statins (HMG-CoA reductase inhibitors) are established lipid-lowering drugs.
- Previous research hinted at improved outcomes in organ transplantation with statin use, but their immunomodulatory role was unclear.
- Major histocompatibility complex class II (MHC class II) molecules are crucial for T lymphocyte activation and immune response regulation.
Purpose of the Study:
- To investigate the potential immunomodulatory effects of statins.
- To determine if statins influence the expression of MHC class II molecules.
- To elucidate the mechanism by which statins might affect immune responses.
Main Methods:
- The study focused on the induction of MHC class II expression by interferon-gamma (IFN-gamma).
- Investigated the role of the transactivator CIITA in MHC class II regulation.
- Examined the effect of statins on the inducible promoter IV of CIITA.
Main Results:
- Statins were found to directly inhibit the IFN-gamma-induced expression of MHC class II molecules.
- This inhibition is specific to inducible MHC class II expression, not affecting constitutive expression.
- Statins act by inhibiting the inducible promoter IV of the transactivator CIITA.
Conclusions:
- Statins function as novel immunomodulators by repressing inducible MHC class II expression.
- This mechanism provides a scientific basis for using statins as immunosuppressors.
- Potential applications include organ transplantation and other immune-related pathologies.
Abstract:
3-Hydroxy-3-methhylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, are effective lipid lowering agents, extensively used in medical practice [Circulation 2000;101:207; J Am Med Assoc 2000;283:2935]. Statins have never been shown to be involved in the immune response, although reports have suggested a better outcome of cardiac transplantation in patients under pravastatin therapy [New Engl J Med 1995;333:621; Circulation 1997;96:1398]. Major histocompatibility complex class II (MHC class II) molecules are directly involved in the activation of T lymphocytes and in the control of the immune response. Whereas only a limited number of specialized cell types express MHC-II constitutively, numerous other cells become MHC-II positive upon induction by interferon-gamma (IFN-gamma) [Annu Rev Immunol 1996;14:301]. This complex regulation is under the control of the transactivator CIITA [Science 1994;265:106]. Recently, we demonstrated that statins act as direct inhibitors of induction of MHC-II expression by IFN-gamma and thus as repressors of MHC-II-mediated T cell activation [Nat Med 2000;6:1399; Swiss Med Wkly 2001;131:41]. This effect of statins is due to inhibition of the inducible promoter IV of the transactivator CIITA. Interestingly, this inhibition is specific for inducible MHC-II expression and does not concern constitutive expression of CIITA and MHC-II. In repressing induction of MHC-II, and subsequent T lymphocyte activation, statins therefore behave as a novel type of immunomodulator. This unexpected effect provides a scientific rationale for suggesting the use of statins as novel immunosuppressors, not only in organ transplantation but in numerous other pathologies as well.